Teladoc, Inc. (TDOC) Receives $37.30 Consensus Target Price from Analysts
Shares of Teladoc, Inc. (NYSE:TDOC) have received an average recommendation of “Buy” from the fifteen research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $37.30.
Several research analysts recently weighed in on TDOC shares. Cowen and Company restated an “outperform” rating and set a $39.00 price target (up previously from $36.00) on shares of Teladoc in a research report on Thursday, August 3rd. KeyCorp began coverage on shares of Teladoc in a report on Wednesday, May 17th. They issued an “overweight” rating and a $37.00 price objective for the company. Piper Jaffray Companies reiterated a “buy” rating and issued a $32.00 price objective on shares of Teladoc in a report on Friday, July 14th. TheStreet downgraded shares of Teladoc from a “c-” rating to a “d” rating in a report on Monday, July 3rd. Finally, BidaskClub downgraded shares of Teladoc from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th.
In other Teladoc news, VP Mark Hirschhorn sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $27.70, for a total value of $2,770,000.00. Following the completion of the transaction, the vice president now owns 80,887 shares of the company’s stock, valued at approximately $2,240,569.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jason N. Gorevic sold 5,600 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $29.57, for a total transaction of $165,592.00. Following the completion of the transaction, the chief executive officer now directly owns 823,861 shares of the company’s stock, valued at approximately $24,361,569.77. The disclosure for this sale can be found here. Insiders sold a total of 207,186 shares of company stock valued at $6,122,950 in the last three months. 5.94% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently modified their holdings of TDOC. State Street Corp boosted its position in shares of Teladoc by 2.5% in the fourth quarter. State Street Corp now owns 381,703 shares of the health services provider’s stock valued at $6,309,000 after buying an additional 9,146 shares in the last quarter. Teachers Advisors LLC boosted its position in shares of Teladoc by 5.3% in the fourth quarter. Teachers Advisors LLC now owns 35,205 shares of the health services provider’s stock valued at $581,000 after buying an additional 1,759 shares in the last quarter. First Mercantile Trust Co. acquired a new position in shares of Teladoc during the first quarter valued at approximately $175,000. Russell Investments Group Ltd. acquired a new position in shares of Teladoc during the first quarter valued at approximately $583,000. Finally, Wells Fargo & Company MN boosted its position in shares of Teladoc by 43.8% in the first quarter. Wells Fargo & Company MN now owns 543,568 shares of the health services provider’s stock valued at $13,589,000 after buying an additional 165,435 shares in the last quarter. 94.51% of the stock is owned by institutional investors.
Shares of Teladoc (NYSE:TDOC) traded up 1.63% during midday trading on Friday, hitting $31.20. The stock had a trading volume of 512,598 shares. Teladoc has a 52-week low of $14.00 and a 52-week high of $36.90. The firm has a 50 day moving average price of $33.60 and a 200-day moving average price of $27.80. The stock’s market cap is $1.77 billion.
Teladoc (NYSE:TDOC) last released its quarterly earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.02. Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The company had revenue of $44.60 million for the quarter, compared to analyst estimates of $44.39 million. During the same quarter last year, the company earned ($0.38) EPS. The firm’s revenue for the quarter was up 68.3% on a year-over-year basis. Equities analysts predict that Teladoc will post ($1.46) EPS for the current fiscal year.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Stock Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related stocks with our FREE daily email newsletter.